A method of treating syndrome of excess mobilization of fat by the body of animals during their pregnancy or lactation and medicines for the treatment of syndrome of excess mobilization of fat

 

(57) Abstract:

The invention concerns a method of treating syndrome of excess mobilization of fat by the body of animals during pregnancy or lactation. In the blood of animals increase the number or activity of somatotropin while appointing sick animals glucose or gluconeogenic substrates, or pre-cursors of glucose. 2 C. and 30 C.p. f-crystals, 4 PL.

The invention relates to the treatment ketoacidotic conditions in agricultural and other animals, especially important from an economic point of view animals such as sheep and cattle.

Associated with ketoacidosis disease are observed when the animals ' energy exceeds its intake through food and the majority of the fats of the body catabolized for reimbursement of its shortage. While there is a shortage of glucose and blood ketone bodies are collected. (Veterinary Medicine, 7-th Edition, by Blood, DC & Radosbib, OM Pull: Bailliere Tindall, 1989).

In sheep ketoacidosis (toxemia of pregnancy) are usually seen in early pregnancy, especially in animals bearing more than one uterine fetus or the fetus. The reason for this is full-time is beremennosti often have difficulties in the birth of lambs. In addition, especially when the lamb is killed in the womb, the sheep developed metritis, which ultimately leads to toxemia.

In highly productive dairy cattle moderate ketoacidosis is common during early lactation and due to very high demand for glucose and other nutrient substrates for the biosynthesis of milk. Can be observed and clinical ketoacidosis. Cows that are excessively well-fed, it may suffer more seriously, when excessive mobilization of body fat leads to their accumulation in the liver. This condition is known as the syndrome of fat cows.

Treatment ketoacidotic States, refunds will normally glucose or its predecessors, for example, intravenous glucose or dextrose, oral appointment propionate, glycerol, propylene glycol, molasses, etc. Used in the future, the term "glucose" is referring to her predecessors and substitutes. The purpose of the glucose may be accompanied by injections of insulin. Corticosteroids or anabolic steroids can also be used (see, for example, the Internal non-communicable diseases in farm animals edited by I. G. of Tarabrina. -M.: Agropromizdat, 1985, 288 - 295).

In animal husbandry somatotropin and privately and predecessors, used mainly to increase the gain of cattle and improve lactation (see U.S. patent N 4792546, class A 61 K 37/36, 1988).

Now it was unexpectedly discovered that the phenomenon of excessive mobilization of body fat during pregnancy or lactation, manifested in the form of toxemia of pregnancy or syndrome fat cows, can be cured or prevented by the appointment of diseased animals glucose, her surrogates or precursors with increasing concentration or activity of growth hormone in the blood. The level of growth hormone in the blood can be increased by the appointment of somatotropin or somatotropinomas factors. The activity of the growth hormone can be increased by the appointment of antibodies, such as antiidiotypic antibodies.

The present invention thus relates to a method of treating excessive mobilization of body fat in animals during pregnancy or lactation, which includes the appointment of diseased animals glucosyl activity of somatotropin.

Manifestations of this syndrome are toxicosis of pregnancy and the syndrome of fat cows.

Glucose may be administered as such or in the form of one of its predecessors, as noted earlier. Toxemia of pregnancy is often complicated by hypocalcemia and in such cases it is convenient to assign glucose in the form of borogluconate calcium as one of its predecessors. Other forms of precursors of glucose includes dextrose, molasses, corn syrup, molasses, propionate, glycerin, propylene glycol and other suitable compounds that are metabolized to 3-piece.

Cross-species activity of hormones are well known from the literature. So, it is well known, for example, a biologically active somatotropin in relation to sheep and animals of other species. Therefore, any biologically active hormone or factor, releasing or activating the hormone that effect on animals under normal conditions, can be used.

The hormones used in the present invention, can be associated with metals such as zinc, iron, calcium, magnesium, manganese, sodium, potassium or their salts. When using this associated with metal hormone, it is preferable that istotnie additive salts with inorganic acids, and salts with polyvalent organic cations.

The term "hormone" and "hormonology factor" used in the present invention, relate to substances which possess biological activity and chemical structure that is similar to the activity and structure of compounds naturally produced in the animal body. They include natural products and obtained by synthetic hormonal composition having the same or similar amino acid sequences that have natural ingredients. Such synthetic products can be obtained by chemical modification of naturally occurring compounds or may be obtained by biotechnological methods, for example, expression or bacteria, such as E. coli. Products for use in the present invention include, therefore, natural and synthetic hormones and gormonozavisimye factors and their biologically active analogs having similar chemical structure. The activity of the growth hormone can be increased by using a method of immunization against growth hormone and the use of monoclonal antibodies. Insulinogenic growth factor I (IGF-I), which may mediate the effects of growth hormone covered by the concept of "agent that enhances the activity of somatotropin", use the factory worker or the activator are assigned in the usual manner and by any conventional means. So, glucose or its precursor may, for example, be administered orally, intravenously or subcutaneously. They can be administered in a single daily dose, or other appropriate or acceptable intervals, for example, 2 to 3 times a day. Hormonal drug is usually administered once daily by subcutaneous injection of a solution in a suitable solvent, such as buffered isotonic saline solution. However, you can assign a different frequency or in formulation with delayed release of active principle, as, for example, in the form of an oil suspension in natural oil, in the form of salts of fatty acids or resin, or other methods to ensure long-term release of the active agent from the zone of injection or implantation. The period required for treatment depends on the type of animal and the severity of the disease and is usually from about 5 days to about 56 days. Glucose and hormonal drug can be administered simultaneously or put in different terms.

The amount of glucose or predecessor glucose obtained sick animals depends on the species and weight of his body. It is usually from 0.4 to 2 g/kg of body weight. So, for sheep total daily dose is from MF for cattle it usually is in the range from about 100 to about 500 g/day, preferably from about 200 to about 400 g/day.

Similarly assigned dose hormonal drug depends on the species and weight of his body. Further clarification of dosage depends on the specific hormonal drug and its activity. The choice methadone doses should be based on effectiveness and can easily be done by a qualified technician. When the hormonal drug is a growth hormone or releasing this hormone factor, the required amount of this product is usually the same as its effective amount needed to stimulate growth in healthy animals. The required dosage can be easily determined by a qualified technician. Basically desired amount of growth hormone is in the range from 0.02 to 0.25 mg/kg of body weight. Thus, the daily dose is from about 10 to about 50 mg for cattle and from about 4 to about 15 mg for sheep, which is the preferred norm. For releasing hormone, growth factor or its chemical derivative dosage depends on the activity of specific compounds. Used calironia the use of animals. This number is typically located within 1/3 of the amount of the hormone, but can vary widely. A qualified specialist is not difficult to determine the appropriate number of connections.

The method according to the present invention can be used in relation to any animal suffering from associated with ketosis diseases, especially in regard to animals that are important from an environmental point of view, such as cattle and sheep. A particularly valuable application of the method in relation to sheep, because you know that sheep suffering from toxemia of pregnancy, often experience difficulties in the birth of lambs. In addition, the method is very valuable because it prevents a situation in which the lamb is killed in the womb that causes sheep metritis and ultimately the toxaemia. It is a fact and a high distribution of toxicosis of pregnancy in sheep, waiting for the twins, which is especially important from an economic point of view. The use of the method according to the present invention for this reason, it is especially important for the treatment of sheep.

The second aspect of the present invention relates to the use of growth hormone, or somatotropin precursor, or somatotropinomas factor, jirama excess mobilization of fat in animals during pregnancy or lactation, manifesting in the form of toxemia of pregnancy or syndrome fat cows have important from an economic point of view animals on treatment of animals glucose. The invention also relates to formulations containing one or more of the mentioned agents suitable for use in the process of such treatment. The formulations can be in the form of solutions in suitable veterinary acceptable solvent. Such a solvent can be, for example, water or a buffered isotonic saline solution. Alternatively, they can be administered in the form of formulations with a slow release of the active agent, such as oil suspension in natural oils, in the form of salts of fatty acids or resins or other injectable or implantable forms. They can be mixed with the veterinary acceptable excipients, such as preservatives or antioxidants, for example, propylgallate.

The invention is further described with reference to the following test results. The latter are intended only to illustrate the invention and should not be construed in a restrictive sense. Possible variants of the presented techniques can easily be determined qualified Spezia sheep, suffering from toxemia of pregnancy.

Materials and methods.

The study covers sheep clinically affected with toxemia of pregnancy. All sheep were treated with intravenous injections of glucose and oral assignments glycol, but half of them also received recombinant bovine somatotropin. Freshly prepared somatotropin were injected daily subcutaneously at a dose of 0.15 mg/kg body weight.

In the experience were used 34 sheep affected by toxemia of pregnancy. Of these 4 animals died within 24 h after the start of the experiment, partly as a result postvaccinal complications. The remaining 30 sheep were divided into equal groups. The animals of one group (control) received daily intravenous injections of glucose and twice-daily oral propylene glycol. Animals in a serious condition received glucose twice a day. Animals of the other group (experimental) received the same therapy and advanced subcutaneously with recombinant bovine somatotropin in a dose of 0.15 mg/kg of body weight.

Comments.

Survived 11 sheep in the experimental group (73%) and 12 sheep in the control group (80%). All but one of the deceased, then brought lambs. The time during which after the birth of the lambs came death is but). The usual cause of death were complications during childbirth and metritis. The duration of treatment was lower in animals from the experimental group (6,5 + 1.2 days 7.8 + 1,47 days in animals of the control group). Treated with somatotropin sheep were evaluated as having the best state - "apparent liveliness than sheep in the control group.

Animals of the control group yielded 16 lambs, and the animals of the experimental group of 20 lambs. Childbirth died 14 sheep of the control group and 8 sheep in the experimental group. All lambs born alive survived.

Somatotropin had no adverse effect on sheep suffering associated with ketosis state. Extremely high survival of sheep makes a clear differentiation of treatment effectiveness, however, there is a tendency to lower fetal mortality of lambs, longer survival of sheep after the birth of lambs and improve the overall condition that appropriately discussed in the future.

Short report and results.

Animals.

34 sheep with toxemia of pregnancy, 4 sheep were killed in the first 24 hours In the experiment were subjected to treatment 15 sheep.

Treatment.

Control; glucose intravenously daily (in severe cases up to (in severe cases twice a day);

propylene glycol orally twice a day;

bovine somatotropin subcutaneously 0.15 mg/kg of body weight daily (PL. 1).

Experience 2. The use of recombinant bovine somatotropin and propylene glycol compared to the use of glucose and propylene glycol in the treatment of toxemia of pregnancy.

Materials and methods.

In experiment 9 were used sheep. They were all from one farm, where there was a serious outbreak of toxemia of pregnancy and hypocalcemia. Each sheep in the beginning of the experiment was introduced 50 ml of 40% borogluconate calcium.

In the beginning of the experiment, each sheep of the control and the experimental group received intravenous glucose and propylene glycol, as in the previous experience. Subsequently, however, the animals of the experimental group received 60 ml of propylene glycol twice a day and did not receive glucose. Animals of the experimental group received a daily injection of bovine somatotropin, as in the previous experience. The control group was conducted as in experiment 1.

Comments.

All sheep in both groups survived. Despite the fact that the animals of the control group received daily intravenous glucose, while the animals of the experimental group, treated with somatotropin, its not received, had months and the results.

Animals.

9 sheep with toxemia of pregnancy and hypocalcemia. In the beginning of the experiment all animals received borogluconate calcium. In the experimental group was 6 animals in the control and 3 animals.

Treatment.

Control; glucose intravenously daily in severe cases, twice a day);

propylene glycol orally twice a day.

Experience: glucose intravenous only on the first day;

propylene glycol orally twice a day;

bovine somatotropin podkuyko 0.15 mg/kg of body weight daily (see table. 2).

Experience 3. The use of recombinant bovine somatotropin and propylene glycol compared to the use of glucose and propylene glycol in the initial injection in the treatment of toxemia of pregnancy.

Materials and methods.

Experience covered 57 sheep clinically affected with toxemia of pregnancy. Animals were randomly distributed between the experimental and control groups. Animals of the experimental group initially received an injection of 100 Il of 50% dextrose mixed with 60 ml of propylene glycol oral and additionally subcutaneous injection of 0.15 mg/kg bovine somatotropin. In the following days, the animals received in the morning only the injection of somatotropic received the same initial therapy, but without a prescription somatropin. Subsequently, they received an injection of 100 ml of 50% dextrose in the morning and oral propylene glycol in the morning and after lunch.

Comments.

In this experiment, no difference was found in the evaluation of the General condition and clinical status between animals experimental and control groups. In the first 24 h of experience died 8 sheep (2 from the experimental group and 6 from the control group). This was significantly more than in the previous experiments. The overall mortality rate was 11 individuals in the experience and 20 individuals in the control (34% and 80%, respectively). This clearly shows a significant difference between the survival rates in the two groups, i.e. 21 individual experience and 5 animals in the control, which is 66% and 20%, respectively, and these values increase to 70% and 26% when the animals killed in the first 24 h are not taken into account. When using the mean square deviations this result shows the high significance of differences (p<0,001) between the two groups.

In this experiment, the animals suffered severe toxemia of pregnancy that was the result of higher overall mortality. Treatment with somatotropin and propylene glycol resulted in a marked enhancement of the survival of the sheep and the increase in the number of live s, treated with somatotropin, had a higher survival rate and a greater number of lambs born alive. It seems that many of the sheep in the control group initially refused to treatment with glucose and propylene glycol, but subsequently lost in the moment of birth of lambs that died because of the stress of childbirth or because of the death of the lamb in the womb.

Short report and results.

Animals.

57 sheep with toxemia of pregnancy. In the experimental group was 32 animals in the control and 25 animals.

Treatment.

Control: dextrose intravenously daily:

propylenglycol orally twice a day.

Experience: dextrose intravenously only on the first day;

propylene glycol orally twice a day;

bovine somatotropin subcutaneously 0.15 mg/kg of body weight daily (see table. 3).

Experience. 4 the Use of recombinant bovine somatotropin in the form of a recipe with a long release.

Materials and methods.

Two groups of sheep received 100 ml of 50% dextrose intravenously at the beginning of the experiment and subsequently at 60 ml of propylene glycol twice a day. Animals of the experimental group received a single injection of 320 mg of the preparation Animal Health). The injection is carried out, using the applicator, which allows to distribute the half portion (160 mg).

Comments.

From 15 sheep experimental group one died in the first 24 h, and the other died after the birth of a lamb. Survivors 13 sheep brought 17 of the living and the 13 dead lambs. The control group included 13 sheep, of which 3 died in the first 24 h, 3 died before the birth of lambs, and one died after birth (born two dead lamb). Survivors 6 sheep brought 6 living, and 8 dead lambs. The overall survival rate was 47% in the control and 87% in the experiment (p = < 0,05). With the exception of the calculation of the victims in the first 24 h sheep survival rate was in control of 60% and in the experience of 93% (p = < 0,05). The scoring of the clinical condition of the animals of the control group was lower (3,81 + 0,95) than the score of the clinical condition of the animals of the experimental group (4,40 + 0,78), while the score of the General condition was 1,88 + 0,30 for the animals of the control group and 2.00 + 0,33 for the animals of the experimental group. In the control group animals were treated 7,17 + 4.26 deaths a day, and in the experimental group between 6.08 + 2.75 days. When most animals were studied blood glucose level was higher in animals from the experimental group, but the level of beta-hydroxybutyl is a rule higher in animals from the experimental group, while the level albasini and globulin was lower. The average level of urea in plasma was higher in animals from the experimental group, as usually was the case with level creatinekinase. The levels of cortisol in plasma was higher in the beginning of the experiment and then decreased (see table. 4).

Experience 5. The use of recombinant bovine somatotropin in the form of injection for the treatment of syndrome of fat cows.

A high level of postpartum infections occurring in the dairy herd, diagnosticums as a syndrome of fat cows. Recombinant bovine somatotropin was used in addition to the traditional treatment of cows after calving. This treatment was also used for the treatment of cows prior to calving. Blood samples were taken from each animal before treatment and twice a week until the end of treatment. Concentrations of glucose, beta-hydroxybutyrate, urea, albumin, total protein and calcium were determined and compared in animals experimental and control group.

Materials and methods.

Animals showing clinical symptoms of the disease or inspiring fears of rapidly deteriorating, were held separately from the main part of the dairy herd. For the experiment was selected 11 of these animals and their assessment of what slavnosti (Advisory leaflet 612; 1978). All animals were clinically examined, and any anomalies registered. They were divided into two groups 5 and 6 animals, their distribution on the General status, clinical symptoms, and the expected timing of calving was assessed as equally likely in both groups. The animals of one group were receiving 640 mg bovine somatropin (Sonidobove, Elanco) subcutaneously into the lateral surface of the body from the tail to the shoulder. It was assumed that this drug will be active within 28 days. It was estimated General condition 10 heifers and they were also subjected to treatment with somatotropin. This group was selected so that the animals could be subjected to treatment at least 2 weeks before expected calving. For the experimental group, a control group of 8 animals was chosen on the basis of assessment of the General condition of the animals and the expected date of calving. Animals of the control group not treated. Six other animals were treated at a later date, when the action of growth hormone is more effective. Blood samples were collected from all cows twice a week until the end of treatment.

Samples were collected from the abdominal blood vessels of the rear part of the body, using the evacuation tube containing the ducks.

From each cow took two blood samples, one for determining the concentration of glucose using potassium oxalate and sodium fluoride as anticoagulant, and second to determine other biochemical parameters, using heparinate lithium.

Plasma was separated from whole blood in the same day by centrifugation and stored frozen at -20oC until the end of the experience. Samples were obtained from each animal were analyzed sequentially to reduce the probability of error in the determination process. Have used auto analyzer Guifford 58A 300 and a standard analytical technique. Was measured the following biochemical parameters: the content of total protein, albumin, urea, beta-hydroxybutyrate, calcium and glucose.

Comments.

Mean values and standard error of the averages were calculated for biochemical parameters within each group for each day of sampling. The corresponding static significance of observed deviations of the mean values between groups was evaluated using student's criterion.

Results.

The obtained data do not prove that plasma concentrations of glucose, beta-hydroxybutyrate is inoe decrease in the average plasma concentration of urea was observed in cows before calving, if they were treated with somatotropin. This could be due to increased protein anabolism. Subjective impressions of the clinical picture was allowed to believe that somatotropin useful in the treatment of cows suffering from the syndrome of fat cows.

1. A method of treating syndrome of excess mobilization of fat by the body of animals during their pregnancy or lactation, providing for the appointment of a sick animal glucose, characterized in that the animals administered glucose and/or its predecessors in conjunction with veterinary-effective amount of an agent that increases in the blood content of somatotropin, or agent that enhances the activity of somatotropin.

2. The method according to p. 1, characterized in that the syndrome manifests itself in the form of toxemia of pregnancy.

3. The method according to p. 1, characterized in that the syndrome manifests itself in the form of the syndrome fat cows.

4. The method according to each of paragraphs.1 to 3, wherein the agent that increases the content of somatotropin, or an agent that enhances the activity of somatotropin, is a hormone or hormonology factor.

5. The method according to p. 4, wherein the hormone is somatotropin or predecessor Somatom the manual on p. 6, characterized in that the bovine growth hormone is recombinant bovine somatotropin.

8. The method according to each of paragraphs.1 to 3, characterized in that the agent enhances the activity of somatotropin are antibodies.

9. The method according to p. 8, characterized in that the antibodies are antibiotypes antibodies.

10. The method according to each of paragraphs.1 to 3, characterized in that the agent enhances the activity of somatotropin, is the agent for immunization against somatostatin.

11. The method according to each of paragraphs.1 to 3, characterized in that the agent enhances the activity of growth hormone is insulin-like growth factor I (IGF-I).

12. The method according to each of paragraphs.1-11, characterized in that the intake of glucose provide intravenous glucose or dextrose or oral assignment propionate, glycerol, propylene glycol, molasses, starch syrup, molasses or other veterinary-acceptable substances, metabolisable 3-With-fragment.

13. The method according to each of paragraphs.1-12, characterized in that the intake of glucose provide appointment borogluconate calcium.

14. The method according to each of paragraphs.1-13, characterized in that under the animals understood vainauskas perspective, animals are sheep and cattle.

16. The method according to p. 15, characterized in that important from an economic point of view, animals are sheep.

17. Application somatotropinomas factor or agent that enhances the activity of somatotropin, as medicines for the treatment of syndrome of excess mobilization of fat by the body of animals during pregnancy or lactation are important from an economic point of view the animals on the background of treatment with glucose.

18. Application under item 17, characterized in that the syndrome manifests itself in the form of toxemia of pregnancy.

19. Application under item 17, characterized in that the syndrome manifests itself in the form of the syndrome fat cows.

20. Application for each of the PP.17-19, wherein the agent that increases the content of somatotropin, or an agent that enhances the activity of somatotropin, is a hormone or hormonology factor.

21. Application under item 20, wherein the hormone is a growth hormone or somatotropin precursor.

22. Application under item 21, wherein the hormone is bovine somatotropin.

23. Application under item 22, wherein the bovine somatotropin is the activity of recombinant somatotropin, are antibodies.

25. Application under item 24, wherein the antibodies are antiidiotypic antibodies.

26. Application for each of the PP.17-19, wherein the agent enhances the activity of somatotropin, is the agent of immunization against somatostatin.

27. Application for each of the PP.17-19, wherein the agent enhances the activity of growth hormone is insulin-like growth factor I (IGF-I).

28. Application for each of the PP.17 to 27, characterized in that the intake of glucose provide intravenous glucose or dextrose or oral assignment propionate, glycerol, propylene glycol, molasses, corn syrup, molasses and other veterinary acceptable substances, metabolisable 3-With-fragment.

29. Application for each of the PP.17 to 27, characterized in that the receipt of glucose provide appointment borogluconate calcium.

30. Application for each of the PP.17-29, characterized in that under the animals are understood to be important from an economic point of view the animals.

31. Application on p. 30, characterized in that important from an economic point of view, animals are sheep and cattle who are sheep.

 

Same patents:

The invention relates to stable pharmaceutical preparation comprising a growth hormone, to a method of manufacturing this drug and use of asparagine for stabilizing drug growth hormone

The invention relates to veterinary

The invention relates to fused polypeptides that do not occur in nature and contain N-terminal part, cleaved by dipeptidyl peptidase IV (DPP IV)
The invention relates to medicine, namely the subject of the invention are tablets based on partially or fully water-soluble natural and/or synthetic polymers selected from rubbers, alginates, Cartagena, starch, pectin and gelatin containing poly-(dimethyl-siloxanes) (Dimethicone, simethicone), and the method of their manufacture
The invention relates to medicine, in particular to methods for treating obesity

The invention relates to oligonucleotides and their derivatives to suppress the expression of isoprenylation, pharmaceutical compositions containing such compounds and to the use of such compositions of oligonucleotides for the treatment or therapy of the human or animal diseases caused by abnormal and/or unregulated proliferation

d-arabinofuranosyl-2-amino-6-methoxy - n-purines" target="_blank">

The invention relates to 9--D-arabinofuranosyl-2-amino-6-methoxy-N-purine and its derivatives and 9--D-arabinofuranosyl-2-amino-6-methoxy-N-purine and its derivatives and pharmaceutical compositions comprising these derivatives of purine, which is active against viral infections in humans caused by the virus stays zoster (VZV)

The invention relates to a substance which can be used for a new purpose, namely as a drug against HIV-1

The invention relates to medicine, in particular to Oncology and for the correction of the depression of hematopoiesis due to chemoradiation therapy

The invention relates to imidazolidinyl macrolides (substances with macrocyclic Laktionova ring), which are useful for mammals in the treatment of autoimmune diseases (such as juvenile diabetes or newly developed diabetes, multiple sclerosis and rheumatoid arthritis, liver disease, inflammation of the choroid eyeball, allergic encephalomyelitis, and glomerulonephritis), immunosuppression, infectious disease treatment and/or prevention of rejections of foreign bodies in transplantation (e.g., transplants, including xenotransplantation, bone marrow, kidney, liver, heart, skin, small intestine, and islet cells of the pancreas), when local treatment of skin diseases associated with inflammation or with an increased proliferation of cells, and cutaneous manifestations immunostimulating diseases (such as psoriasis, diffuse neurodermatitis, contact dermatitis, and other eczematous dermatitises, seborrhoeic eczema, red flat zoster, utricularia vulgaris, the bubble pemphigoid, congenital bullous bullosa, urticaria, angioedema, vasculitis, erythema, skin tinyline leukocytosis, lupus or focal alope the requirement of the respiratory tract, in particular asthma, inflammation of mucosa and blood vessels and infections caused by a virus cytomegaly, when the resistance of microorganisms to the action of drugs, idiopathic thrombocytopenic Purpur, chronic recurrent aphthous stomatitis (Behcet's disease), conjunctivitis, granulomatous disease (Crohn's disease), corroding ulcer of the cornea (Morena), inflammation of the choroid eyeball, acute intraocular inflammation and/or liver problems caused by ischemia

The invention relates to new N-substituted [2R, 3R (2'R, 3'R), 6R, 7S, 8S, 9R, 10R]-3-(2',3'-dihydroxyphenyl-2'-yl)-7-[(2,6-dideoxy-3-C-methyl-3-O--L-RIBO-hexopyranosyl)-oxy] -9-[(3,4,6-trideoxy-3-amino-B-D-Xylo-hexopyranosyl)-oxy] -2,6,8,10,12-pentamethyl-4,13-dioxabicyclo [8,2,1] -tridec-12-EN-5-he-connections with metalinguistically properties, to their salts, the acid products of accession, as well as to pharmaceutical remedies containing these compounds and methods and intermediate products for their production

The invention relates to methods for furostanol glycosides from plant material with antioxidant activity in comparison with structural analogue with similar biological properties, and thereby expands the Arsenal of tools that can be used in medicine as a therapeutic agent

FIELD: medicine.

SUBSTANCE: method involves carrying out hernia removal in intralaminar way. Posterior longitudinal ligament defect is covered with Tacho-Comb plate after having done disk cavity curettage. Subcutaneous fat fragment on feeding pedicle is brought to dorsal surface of radix and dural sac.

EFFECT: enhanced effectiveness of treatment; reduced risk of traumatic complications.

1 dwg

FIELD: medicine, obstetrics, gynecology.

SUBSTANCE: at the background of therapy conducted one should introduce derinate immunomodulator into the body of pregnant woman additionally nasally per 1-2 drops of 0.25%-solution into each nasal canal 5-8 times daily for 3-5 d and - parenterally per 5.0 ml of 1.5%-solution once daily for 3-8 d along with preparation that improves microcirculation and along with antioxidant at a certain sequence, moreover, derinate should be introduced 30-40 min after application of microcirculation-improving preparation, and antioxidant - 20-30 min after derinate's introduction. The present innovation favors decreased edemas, decreased body weight, stabilization of Macluer-Aldrich test that in its turn enables to avoid perinatal losses, decrease the risk for the development of fetoplacental insufficiency and intrauterine fetal infection.

EFFECT: higher efficiency of therapy.

1 ex, 2 tbl

FIELD: medicine, otolaryngology.

SUBSTANCE: the present innovation deals with introducing neomycin sulfate antibiotic in granules prepared by the following technique. Tablet of neomycin sulfate 1.0g should be put into a vial with 100 ml distilled water till tablet's decomposition. Then vial's content should be shaken and kept till suspension sedimentation. In a day one should take 1 ml of supernatant liquid to be put into another vial and diluted with distilled water at 1:100 ratio. This procedure should be repeated 4 times more, moreover, during the last procedure one should apply alcohol for dilution. Then one should transfer the drop of alcoholic solution into a vial with granules out of milk sugar to then shaken and kept open for 1 d till granules" drying up. The suggested preparation should be applied per 1 granule under the tongue, moreover, multiplicity and duration of the above-suggested intake should be matched individually by patient's sensitivity and obtaining the clinic effect. The method enables to improve the value of tonic threshold audiometry by about 30-50 dB, decrease perception threshold of vocal range frequencies and widen the range towards high frequencies.

EFFECT: higher efficiency of therapy.

1 dwg

FIELD: medicine, oncology.

SUBSTANCE: invention relates to a method for treatment of chronic lympholeukosis. Method involves intravenous drop and jet administration of antitumor chemopreparations and carrying out the autochemotherapy. At the 1-st and 8-th day of treatment cyclophosphan in the dose 750 mg/m2, vincristine in the dose 1.4 mg/m2 and doxorubicin in the dose 30 mg/m2 incubated with 200 ml of autoblood are administrated to patients. From the 1-st to 14-th day of treatment prednisolone is used every day in the therapeutic dose. The treatment course is repeated in 30-35 days depending on blood indices and patient state. The total treatment of courses is 4-5. Method provides reducing cardiotoxicity of doxorubicin and cumulative toxicity of chemopreparations that allows carrying out administration of antitumor chemopreparations in the full volume to patients of elderly age groups.

EFFECT: improved method for treatment.

1 ex

FIELD: medicine, oncohematology.

SUBSTANCE: the present innovation deals with treating elderly patients with chronic lympholeukosis accompanied with cardiovascular failure. The method deals with applying chemopreparations and cytoprotector. Moreover, 1 wk before the onset of chemotherapeutic therapy one should prescribe preductal at the dosage of 105 mg daily. At this background one should sample blood out of elbow vein at the volume of 200 ml into a vial with glugicir to centrifuge it, isolate plasma, divide into two portions, add into the 1st vial - cyclophosphan 600-800 mg/sq. m, vincristin 1.4 mg/sq. m, into the 2nd vial - adriamycin 50 mg/sq. m to be incubated for 30 min at 37 C and intravenously injected by drops for patients. Simultaneously, the intake of prednisolone should be prescribed at the dosage of 60 mg/sq. m since the 1st d and during the next 5 d and preductal at the dosage of 105 mg daily during a week, and then 2 wk more at the dosage of 60 mg daily. All the procedures should be repeated in above-mentioned sequence 4-6 times. The method enables to decrease toxic manifestations of chemotherapy while applying adequate dosages of cytostatics, anthracycline antibiotics, among them, at no great manifestations of their toxicity due to preductal's cardioprotective action.

EFFECT: higher efficiency of therapy.

1 ex, 5 tbl

Up!